冠動脈疾患(CAD)(虚血性心疾患)の治療薬パイプライン動向(2015年上半期版)

◆英語タイトル:Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC6034IDB
◆発行日:2015年1月22日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:167
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥212,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥636,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[冠動脈疾患(CAD)(虚血性心疾患)の治療薬パイプライン動向(2015年上半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における冠動脈疾患(CAD)(虚血性心疾患)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・冠動脈疾患(CAD)(虚血性心疾患)の概要
・冠動脈疾患(CAD)(虚血性心疾患)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・冠動脈疾患(CAD)(虚血性心疾患)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・冠動脈疾患(CAD)(虚血性心疾患)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・冠動脈疾患(CAD)(虚血性心疾患)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H1 2015’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 11
Therapeutics Development 12
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Overview 12
Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Comparative Analysis 13
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Therapeutics under Development by Companies 14
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Therapeutics under Investigation by Universities/Institutes 17
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Products under Development by Companies 22
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Products under Investigation by Universities/Institutes 25
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Companies Involved in Therapeutics Development 26
AnGes MG, Inc. 26
AstraZeneca PLC 27
Bayer AG 28
Biosidus S.A. 29
Biscayne Pharmaceuticals, Inc. 30
Bristol-Myers Squibb Company 31
Cardiome Pharma Corp 32
CardioVascular BioTherapeutics, Inc. 33
Eagle Pharmaceuticals, Inc. 34
Gilead Sciences, Inc. 35
Hemostemix Ltd 36
Human Stem Cells Institute 37
Isis Pharmaceuticals, Inc. 38
Juventas Therapeutics, Inc. 39
Lacer, S.A. 40
Lee’s Pharmaceutical Holdings Limited 41
Lonestar Heart, Inc. 42
MedImmune, LLC 43
Merck & Co., Inc. 44
Miltenyi Biotec GmbH 45
Multi Gene Vascular Systems Ltd 46
Nuo Therapeutics, Inc. 47
Pluristem Therapeutics Inc. 48
Regado Biosciences, Inc. 49
The Medicines Company 50
ViroMed Co., Ltd. 51
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
ACP-01 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ALD-201 – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
anacetrapib – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Aptamers for Cardiovascular Diseases – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BAY-606583 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
beperminogene perplasmid – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Biglycan Therapy for Cardiovascular Diseases – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
BIS-5409 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
bivalirudin – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
bivalirudin – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
BQ-123 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
C2 ceramide – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
C6 ceramide – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
cangrelor – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CAP-1002 – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Cryocell – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
CVBT-141H – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Gemacell – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Gene Therapy to Activate VEGF for Ischemia – Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ISIS-APOARx – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
ISIS-CRPRx – Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
JVS-100 – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
LA-419 – Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
MEDI-6012 – Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Monoclonal Antibody to Inhibit CD20 for Cardiovascular Disease – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
MultiGeneGraft – Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
MZ-004 – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy – Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Proteins for Ischemic Heart Disease – Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
ranolazine ER – Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
rivaroxaban – Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Small Molecule for Coronary Artery Disease – Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Stem Cell Therapy for Cardiovascular Disease – Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Stem Cell Therapy for Cardiovascular Diseases – Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Synthetic Peptides to Modulate CD36 Receptor for Ischemic Heart Disease and Macular Degeneration – Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
tirofiban hydrochloride – Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
VM-202 – Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
XL-652 – Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
ZK-001 – Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Recent Pipeline Updates 127
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects 155
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Discontinued Products 158
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Product Development Milestones 159
Featured News & Press Releases 159
Nov 14, 2014: The Medicines Company to Present New Data on Investigational Antiplatelet Agent Cangrelor at 2014 AHA Annual Scientific Sessions in Chicago 159
Oct 27, 2014: The Medicines Company Wins Favorable Judgment in Angiomax (Bivalirudin) Patent Litigation 159
Oct 06, 2014: Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs) 160
Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APO(A)RX At European Society of Cardiology Congress 2014 160
Jul 07, 2014: The Medicines Company Receives Market Authorization Renewal for Angiox (Bivalirudin) from the European Medicines Agency and the European Commission 161
Apr 28, 2014: The Medicines Company Files Petition Against Aurobindo Over Patent Infringement 162
Mar 30, 2014: Analysis of EUROMAX and HORIZONS-AMI Trials of The Medicines Company’s Angiomax Presented at ACC.14 162
Dec 23, 2013: European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company’s Cangrelor 163
Oct 11, 2013: Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT 164
Oct 09, 2013: First Patient Enrolled in Phase III Trial Evaluating The Medicines Company’s Angiomax in Patients Undergoing Peripheral Endovascular Procedures 164
Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 167
Disclaimer 167

[List of Tables]
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 12
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2015 17
Comparative Analysis by Late Stage Development, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Development, H1 2015 20
Comparative Analysis by Unknown Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Development by Companies, H1 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2015 25
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG, Inc., H1 2015 26
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca PLC, H1 2015 27
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2015 28
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biosidus S.A., H1 2015 29
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 30
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bristol-Myers Squibb Company, H1 2015 31
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cardiome Pharma Corp, H1 2015 32
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 33
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 34
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences, Inc., H1 2015 35
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Ltd, H1 2015 36
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2015 37
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 38
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics, Inc., H1 2015 39
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H1 2015 40
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 41
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart, Inc., H1 2015 42
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune, LLC, H1 2015 43
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co., Inc., H1 2015 44
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Miltenyi Biotec GmbH, H1 2015 45
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 46
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H1 2015 47
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pluristem Therapeutics Inc., H1 2015 48
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Regado Biosciences, Inc., H1 2015 49
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H1 2015 50
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co., Ltd., H1 2015 51
Assessment by Monotherapy Products, H1 2015 52
Number of Products by Stage and Target, H1 2015 54
Number of Products by Stage and Mechanism of Action, H1 2015 56
Number of Products by Stage and Route of Administration, H1 2015 58
Number of Products by Stage and Molecule Type, H1 2015 60
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H1 2015 127
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2015 155
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..1), H1 2015 156
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects (Contd..2), H1 2015 157
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2015 158

[List of Figures]
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 12
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 17
Comparative Analysis by Late Stage Development, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Products, H1 2015 20
Assessment by Monotherapy Products, H1 2015 52
Number of Products by Top 10 Targets, H1 2015 53
Number of Products by Stage and Top 10 Targets, H1 2015 53
Number of Products by Top 10 Mechanism of Actions, H1 2015 55
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 55
Number of Products by Top 10 Routes of Administration, H1 2015 57
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 57
Number of Products by Top 10 Molecule Types, H1 2015 59
Number of Products by Stage and Top 10 Molecule Types, H1 2015 59

*** 掲載企業 ***

AnGes MG, Inc.
AstraZeneca PLC
Bayer AG
Biosidus S.A.
Biscayne Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Cardiome Pharma Corp
CardioVascular BioTherapeutics, Inc.
Eagle Pharmaceuticals, Inc.
Gilead Sciences, Inc.
Hemostemix Ltd
Human Stem Cells Institute
Isis Pharmaceuticals, Inc.
Juventas Therapeutics, Inc.
Lacer, S.A.
Lee's Pharmaceutical Holdings Limited
Lonestar Heart, Inc.
MedImmune, LLC
Merck & Co., Inc.
Miltenyi Biotec GmbH
Multi Gene Vascular Systems Ltd
Nuo Therapeutics, Inc.
Pluristem Therapeutics Inc.
Regado Biosciences, Inc.
The Medicines Company
ViroMed Co., Ltd.

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC6034IDB )"冠動脈疾患(CAD)(虚血性心疾患)の治療薬パイプライン動向(2015年上半期版)" (英文:Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。